Q4 Inc. Enhances CRM with Email Integration and New Mobile App
28.2.2023 16:00:00 EET | Business Wire | Press release
Q4 Inc. (TSX: QFOR) (“Q4” or “the Company”), a leading capital markets communications platform provider, is excited to announce new enhancements to Q4 Desktop, an investor relations CRM. Q4 Desktop will offer fully integrated email automation with personalization capabilities that will strengthen outreach strategies for IR professionals. For IROs on the go, a brand new mobile app, Q4 Go, provides a mobile CRM experience to ensure effective management of day to day program activities from anywhere, at any time.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228005530/en/
Email Automation for Modern IR Teams on Q4 Desktop (Graphic: Business Wire)
The integrated email functionality within Q4 Desktop will allow clients to seamlessly send emails directly from their CRM and provide the option to personalize communication to create a custom experience for their capital market contacts. This eliminates the need for complex third party automation tools and removes frustration caused by manual formatting efforts. Through this personalized engagement, it's possible to build automated and trackable communication processes within the CRM that will increase efficiency and improve relationships among the capital markets.
“Our clients asked and we are thrilled to deliver this highly requested functionality to our evolving CRM this quarter,” said Darrell Heaps, Founder and CEO of Q4. “Designed to ensure deliverability, our email integration will enable IROs to track every touchpoint and nurture relationships like never before.”
Q4 Go delivers access to key CRM workflows that are fully integrated into Q4 Desktop, including identifying contacts, advanced search capabilities, and meeting management. This mobile application is built from the same unified data and insights found on Capital Connect, ensuring its scalability in the future and the potential to interface with other critical workflows, like events or analytics.
“The launch of Q4 Go puts access to critical investor insights straight into the hands of IROs at a time when travel and in person events are making a comeback,” remarked Heaps. “With Q4 Go harnessing the power of Capital Connect, the possibilities are endless when it comes to scaling the application and capitalizing on the aggregated value of our massive data set in the future.”
About Q4 Inc.
Q4 Inc. (TSX: QFOR) is a leading capital markets communications platform that is transforming the way publicly traded companies, investors, and investment banks make decisions to efficiently connect, communicate, and engage with each other.
The Q4 Capital Connect platform facilitates interactions across the capital markets through IR website products, virtual events solutions, engagement analytics, investor relations CRM, shareholder and market analysis, surveillance, and ESG tools. Capital Connect is the only holistic capital markets platform that digitally drives connections, analyzes impact, and targets the right engagement to help public companies work faster and smarter.
The company is a trusted partner to more than 2,650 public companies globally, including many of the most respected brands in the world, and maintains an award winning culture where team members grow and thrive.
Q4 is headquartered in Toronto, with offices in New York and London. Learn more at www.q4inc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230228005530/en/
Contact information
Investor Relations: Sara Pearson, ir@q4inc.com
Media Inquiries: Heather Noll, media@q4inc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 10:00:00 EEST | Press release
Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/ Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services. “As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Jap
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 10:00:00 EEST | Press release
The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the project continues to captivate audiences through its
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 10:00:00 EEST | Press release
Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib, is a first-in-class oral dual-node PI3K/AKT/mTOR (PAM) pathway inhibitor, which selectively inhibits S6K and AKT1/3. Rupitasertib was purposefully and rationally designed to target S6K for potent PAM inhibition and AKT1/3 to block the AKT compensatory feedback loop, while sparing AKT2 to avoid hyperglycemia, which we believe will lead to a superior efficacy and safety profile compared to other PAM pathway inhibitors. Under the terms of the agreement, Roche will s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom